Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Rosiglitazone (RSG) is an insulin-sensitizing thiazolidinedione (TZD) that exerts peroxisome proliferator-activated receptor-γ (PPARγ)-dependent and -independent effects. We tested the hypothesis that part of the insulin-sensitizing effect of RSG is mediated through the action of AMP-activated protein kinase (AMPK). First, we determined the effect of acute (30–60 min) incubation of L6 myotubes with RSG on AMPK regulation and palmitate oxidation. Compared with control (DMSO), 200 μM RSG increased ( P < 0.05) AMPKα1 activity and phosphorylation of AMPK (Thr 172). In addition, acetyl-CoA carboxylase (Ser 218) phosphorylation and palmitate oxidation were increased ( P < 0.05) in these cells. To investigate the effects of chronic RSG treatment on AMPK regulation in skeletal muscle in vivo, obese Zucker rats were randomly allocated into two experimental groups: control and RSG. Lean Zucker rats were treated with vehicle and acted as a control group for obese Zucker rats. Rats were dosed daily for 6 wk with either vehicle (0.5% carboxymethylcellulose, 100 μl/100 g body mass), or 3 mg/kg RSG. AMPKα1 activity was similar in muscle from lean and obese animals and was unaffected by RSG treatment. AMPKα2 activity was ∼25% lower in obese vs. lean animals ( P < 0.05) but was normalized to control values after RSG treatment. ACC phosphorylation was decreased with obesity ( P < 0.05) but restored to the level of lean controls with RSG treatment. Our data demonstrate that RSG restores AMPK signaling in skeletal muscle of insulin-resistant obese Zucker rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status
Hardie, D. G. (2003) · Endocrinology · doi:10.1210/en.2003-0982 · Cited by 994 · cited 1×
“AMPK activation causes many metabolic changes that would be beneficial to individuals with type 2 diabetes and the metabolic syndrome, including increased glucose uptake and metabolism by muscle, decreased glucose production by the liver and decreased synthesis, and increased oxidation of FA (16, 39).”
BackgroundMusi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 1×
“(25) reported that the antidiabetic drug metformin (biguanide) increased AMPK 2 activity in type 2 diabetic patients after a 10-wk treatment regimen.”
BackgroundEfficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794 · cited 1×
“Rosiglitazone (RSG) is a member of the thiazolidinedione (TZD) class of oral antidiabetic agents that improve insulin sensitivity in a range of insulin-resistant states (15, 18).”
BackgroundPPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612
Musi, N., Fujii, N., Hirshman, M. F., Ekberg, I., Fröberg, S., Ljungqvist, O., Thorell, A., & Goodyear, L. J. (2001) · Diabetes · doi:10.2337/diabetes.50.5.921 · Cited by 371 · cited 1×
“Previous studies (17, 24, 34, 40) have suggested that altered skeletal muscle AMPK activity may not play a role in obesity and diabetes.”
BackgroundJakobsen, S. N., Hardie, D. G., Morrice, N., & Tornqvist, H. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100483200 · Cited by 238
Wojtaszewski, J. F. P., Birk, J. B., Frøsig, C., Holten, M., Pilegaard, H., & Dela, F. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.082669 · Cited by 170
Perdomo, G., Commerford, S. R., Richard, A.-M. T., Adams, S. H., Corkey, B. E., O'Doherty, R. M., & Brown, N. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403566200 · Cited by 158
AMP-Activated Protein Kinase Is Not Down-Regulated in Human Skeletal Muscle of Obese Females
Steinberg, G. R., Smith, A. C., van Denderen, B. J. W., Chen, Z., Murthy, S., Campbell, D. J., Heigenhauser, G. J. F., Dyck, D. J., & Kemp, B. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0308 · Cited by 97
Self-citation
Cited by
AMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383
AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity.
O’Neill, H. M., Holloway, G. P., & Steinberg, G. R. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.019 · Cited by 364
AMPK as a mediator of hormonal signalling
Lim, C. T., Kola, B., & Korbonits, M. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0063 · Cited by 298
Bandyopadhyay, G. K., Yu, J. G., Ofrecio, J., & Olefsky, J. M. (2006) · Diabetes · doi:10.2337/db06-0062 · Cited by 291
Lee-Young, R. S., Canny, B. J., Myers, D. E., & McConell, G. K. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91208.2008 · Cited by 77
“, glucose uptake and fatty acid oxidation), increased GLUT-4 and hexokinase II levels, and increased markers of mitochondrial biogenesis in skeletal muscle (5, 15, 17, 21, 23, 37).”
BackgroundInfluential
Metadata
- Authors
- Lessard, S. J., Chen, Z.-P., Watt, M. J., Hashem, M., Reid, J. J., Febbraio, M. A., Kemp, B. E., & Hawley, J. A.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2006-02
- Volume
- 290
- Issue
- 2
- Pages
- E251-E257
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2051636465
- Cited by
- 60
- References
- 9
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle. https://app.cochat.ai/papers/10.1152/ajpendo.00096.2005
- The paper
- Lessard, S. J., Chen, Z.-P., Watt, M. J., Hashem, M., Reid, J. J., Febbraio, M. A., Kemp, B. E., & Hawley, J. A. (2006). Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00096.2005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.